Cocrystal Pharma Shares Soar After FDA Clears Phase 1b Norovirus Trial

Introduction

Cocrystal Pharma Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics. The company utilizes a structure-based drug discovery platform to target the replication machinery of influenza viruses, SARS-CoV-2, hepatitis C, and noroviruses. Cocrystal is working to develop antiviral treatments that are designed for safety and efficacy.

Corporate Structure and Leadership

Headquartered in Bothell, Washington, Cocrystal Pharma employs between 11 and 50 people. Its management team combines scientific and financial expertise:

• Sam Lee, Ph.D. – Co-Chief Executive Officer and President. Dr. Lee has over 25 years of experience in anti-infective drug discovery, including work on PI3K delta inhibitors at Icos Corporation and postdoctoral training in viral biochemistry at Stanford University.
• James J. Martin – Co-Chief Executive Officer and Chief Financial Officer. Mr. Martin has over 25 years of finance and management experience in public health science and medical device companies.

Antiviral therapeutics by little plant

Recent Developments

On September 10, 2025, Cocrystal Pharma received a Study May Proceed letter from the U.S. Food and Drug Administration. The letter permits a Phase 1b human challenge study of CDI-988 for the prevention and treatment of norovirus infections, with dosing planned before the end of 2025.

Between September 8 and 10, 2025, the company participated in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. Presentations included data on CC-42344, an investigational influenza antiviral candidate that has demonstrated a significant in vitro potency against the 2024 H5N1 avian flu strain compared to oseltamivir.

In May 2025, Cocrystal Pharma published its first-quarter fiscal 2025 financial results, reporting a net loss of $12.6 million for the trailing twelve months and $4.77 million in cash and cash equivalents as of March 31, 2025.

Financial and Strategic Analysis

As of September 12, 2025, the company’s shares closed at $2.7897, an increase of 93.73% from the prior close, on a trading volume of 23,170,125 shares. Key metrics include:

• Market capitalization: $14.8 million
• 52-week trading range: $1.12 – $3.26
• Beta (5Y monthly): 2.28
• Trailing P/E: N/A (loss-making)
• EPS (TTM): –$1.24
• Total cash (most recent quarter): $4.77 million
• Total debt/equity ratio (most recent quarter): 31.09%
• Levered free cash flow (TTM): –$8.74 million

Cocrystal’s structure-based platform supports a pipeline that includes candidates for pandemic and seasonal influenza, norovirus, and coronaviruses. The development of oral and inhaled formulations may address clinical needs in both hospital and outpatient settings.

Market Position and Industry Context

Cocrystal operates in the antiviral therapeutics sector, competing with established pharmaceutical firms and clinical-stage biotech companies. The management of influenza and norovirus represents significant market potential: the U.S. annual flu burden is estimated at $11.2 billion, while norovirus causes an estimated 685 million gastroenteritis cases worldwide with no approved treatments. Cocrystal’s approach, including its development of oral delivery candidates, aligns with addressing these unmet medical needs while navigating clinical and regulatory risks inherent to early-stage drug development.

tl;dr

As of September 12, 2025, COCP shares increased by 93.73% to $2.79 following FDA clearance for a Phase 1b norovirus challenge study of CDI-988, planned to start before the end of 2025. Data presented at the H.C. Wainwright conference from September 8–10 highlighted CC-42344’s potency compared to oseltamivir against H5N1. Financial results for Q1 2025 reported a $12.6 million net loss and $4.77 million in cash, reflecting ongoing clinical programs.